BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company has positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the Company’s ALTACE® (ramipril) diuretic fixed-dose combination product. The Company is continuing to evaluate the trial data and expects to present the findings in detail at an upcoming scientific conference.
